A detailed history of Brown Brothers Harriman & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 2,478 shares of VRTX stock, worth $1.12 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,478
Previous 2,504 1.04%
Holding current value
$1.12 Million
Previous $1.17 Million 1.79%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $11,960 - $13,150
-26 Reduced 1.04%
2,478 $1.15 Million
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $40,852 - $50,495
104 Added 4.33%
2,504 $1.17 Million
Q1 2024

May 10, 2024

SELL
$407.69 - $446.08 $46,476 - $50,853
-114 Reduced 4.53%
2,400 $1 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $64,827 - $77,618
-189 Reduced 6.99%
2,514 $1.02 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $28,068 - $30,084
83 Added 3.17%
2,703 $939,000
Q2 2023

Aug 07, 2023

BUY
$314.42 - $351.91 $28,926 - $32,375
92 Added 3.64%
2,620 $922,000
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $16,710 - $19,062
59 Added 2.39%
2,528 $796,000
Q4 2022

Feb 09, 2023

SELL
$285.76 - $321.48 $2,857 - $3,214
-10 Reduced 0.4%
2,469 $712,000
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $4,381 - $4,888
16 Added 0.65%
2,479 $718,000
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $10,338 - $12,872
44 Added 1.82%
2,463 $694,000
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $18,599 - $21,921
84 Added 3.6%
2,419 $631,000
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $57,882 - $73,068
-327 Reduced 12.28%
2,335 $513,000
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $9,250 - $10,352
-51 Reduced 1.88%
2,662 $483,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $30,373 - $35,818
-162 Reduced 5.63%
2,713 $547,000
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $121,313 - $141,407
-586 Reduced 16.93%
2,875 $618,000
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $645,250 - $860,572
3,117 Added 906.1%
3,461 $818,000
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $31,341 - $41,116
-139 Reduced 28.78%
344 $100,000
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $173,799 - $215,594
-870 Reduced 64.3%
483 $115,000
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $133,034 - $178,680
798 Added 143.78%
1,353 $296,000
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $8,477 - $9,541
51 Added 10.12%
555 $94,000
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $15,308 - $17,704
93 Added 22.63%
504 $92,000
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $18,992 - $22,585
-116 Reduced 22.01%
411 $76,000
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $23,546 - $29,792
155 Added 41.67%
527 $87,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $335 - $385
2 Added 0.54%
372 $72,000
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $31,184 - $36,371
214 Added 137.18%
370 $63,000
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $4,396 - $5,136
-29 Reduced 15.68%
156 $25,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $1,235 - $1,399
9 Added 5.11%
185 $28,000
Q2 2017

Aug 14, 2017

BUY
N/A
176
176 $23,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.